Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis-Reference-Cited by-同舟云学术

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis

Published:2018-06-25 Issue:2 Volume:52 Page:1800230
ISSN:0903-1936
Container-title:European Respiratory Journal
language:en
Short-container-title:Eur Respir J

Author:

Flaherty Kevin R.,Fell Charlene D.,Huggins J. Terrill,Nunes Hilario,Sussman Robert,Valenzuela Claudia,Petzinger Ute,Stauffer John L.,Gilberg Frank,Bengus Monica,Wijsenbeek Marlies

Funder

F. Hoffmann-La Roche

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Reference33 articles.

1. Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis

2. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

3. American Cancer Society. Cancer Facts & Figures 2017. 2017. www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf Date last accessed: January 15, 2018.

4. Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium

5. Cancer statistics, 2018

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Induced pluripotent stem cell-derived mesenchymal stem cells reverse bleomycin-induced pulmonary fibrosis and related lung stiffness;Biomedicine & Pharmacotherapy;2024-09

2. Current challenges in the diagnosis and management of idiopathic pulmonary fibrosis in Japan;Respiratory Investigation;2024-09

3. Targeting the PI3K/mTOR pathway in idiopathic pulmonary fibrosis: Advances and therapeutic potential;Bioorganic & Medicinal Chemistry;2024-09

4. Atropisomerism Observed in Galactose-Based Monosaccharide Inhibitors of Galectin-3 Comprising 2-Methyl-4-phenyl-2,4-dihydro-3H-1,2,4-triazole-3-thione;Journal of Medicinal Chemistry;2024-08-05

5. Novel therapeutic strategies and drugs for idiopathic pulmonary fibrosis;Archiv der Pharmazie;2024-07-03